Compare Archer-Daniels-Midland Co (ADM) vs AstraZeneca plc (AZN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer-Daniels-Midland Co vs AstraZeneca plc — how do they compare? Archer-Daniels-Midland Co trades at $79.93 (market cap $37.69B), while AstraZeneca plc trades at $189.89 (market cap $294.08B). The key difference: AstraZeneca plc is far larger — about 7.8× Archer-Daniels-Midland Co's market cap, and Archer-Daniels-Midland Co pays the higher dividend (2.66%). Which is the better fit depends on your goals.
| ADM | AZN | |
|---|---|---|
Market Cap | $37.69B | $294.08B |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $209.48 |
52-Week Low | $53.54 | $137.44 |
Enterprise Value | $47.72B | $320.32B |
Dividend Yield | 2.66% | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
AstraZeneca (AZN) trades at $193.12, down 1.04% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, marking a 17.4% profit margin. Recent news highlights strategic collaborations and regulatory approvals for key drugs like Enhertu, reinforcing growth prospects.
AZN presents a favorable outlook with robust earnings growth and a solid pipeline, though valuation multiples like a P/E of 28.64 suggest premium pricing. Risks include competitive pressures and trial outcomes, but analyst consensus leans bullish with 47.5% buy ratings. Institutional interest remains high, supporting potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
